Guerra Geno, Wendt George, McCoy Lucie, Hansen Helen M, Kachuri Linda, Molinaro Annette M, Rice Terri, Guan Victoria, Capistrano Lianne, Hsieh Allison, Kalsi Veruna, Sallee Jaimie, Taylor Jennie W, Clarke Jennifer L, Almaraz Eduardo Rodriguez, Wiencke John K, Eckel-Passow Jeanette E, Jenkins Robert B, Wrensch Margaret, Francis Stephen S
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
Neuro Oncol. 2025 Jun 21;27(5):1385-1398. doi: 10.1093/neuonc/noae275.
Temozolomide (TMZ) treatment has demonstrated a variable impact on glioma prognosis. This study examines associations of survival with DNA repair gene germline polymorphisms among glioma patients who did and did not have TMZ treatment. Identifying genetic markers which sensitize tumor cells to TMZ could personalize therapy and improve outcomes.
We evaluated TMZ-related survival associations of pathogenic germline SNPs and genetically predicted transcript levels within 34 DNA repair genes among 1504 glioma patients from the University of California San Francisco Adult Glioma Study (UCSF AGS) and Mayo Clinic, whose diagnoses spanned pre- and post-TMZ eras within the major known glioma prognostic molecular subtypes.
Among those who received TMZ, 5 SNPs were associated with overall survival, but not in those who did not receive TMZ. Only rs2308321-G, in MGMT, was associated with decreased survival (hazard ratio = 1.21, P = .019) for all glioma subtypes. Rs73191162-T (near UNG), rs13076508-C (near PARP3), rs7840433-A (near NEIL2), and rs3130618-A (near MSH5) were only associated with survival and TMZ treatment for certain subtypes, suggesting subtype-specific germline chemosensitization. Genetically predicted elevated expression of PNKP, compared to normal brain expression, was associated with markedly poor survival in TMZ-treated patients with isocitrate dehydrogenase (IDH)-mutant and 1p/19q non-codeleted gliomas (P = .015), with a median difference of over 70 months in overall survival times. Similarly, NEIL2 and TDG expressions were associated with altered TMZ-related survival only among certain subtypes.
Functional germline alterations within DNA repair genes were associated with TMZ sensitivity, measured by overall survival among adults with glioma. These variants should be evaluated in prospective analyses and functional studies.
替莫唑胺(TMZ)治疗对胶质瘤预后的影响具有变异性。本研究调查了接受和未接受TMZ治疗的胶质瘤患者中DNA修复基因种系多态性与生存的关联。识别使肿瘤细胞对TMZ敏感的遗传标记可实现个性化治疗并改善预后。
我们评估了来自加利福尼亚大学旧金山分校成人胶质瘤研究(UCSF AGS)和梅奥诊所的1504例胶质瘤患者中34个DNA修复基因内致病种系单核苷酸多态性(SNP)与基因预测转录水平与TMZ相关的生存关联,这些患者的诊断跨越了主要已知胶质瘤预后分子亚型中TMZ时代的前后。
在接受TMZ治疗的患者中,5个SNP与总生存相关,但在未接受TMZ治疗的患者中则不然。仅MGMT基因中的rs2308321 - G与所有胶质瘤亚型的生存降低相关(风险比 = 1.21,P = 0.019)。Rs73191162 - T(UNG附近)、rs13076508 - C(PARP3附近)、rs7840433 - A(NEIL2附近)和rs3130618 - A(MSH5附近)仅与某些亚型的生存和TMZ治疗相关,提示亚型特异性种系化学敏感性。与正常脑表达相比,基因预测的PNKP表达升高与TMZ治疗的异柠檬酸脱氢酶(IDH)突变型和1p/19q未缺失胶质瘤患者的显著不良生存相关(P = 0.015),总生存时间中位数差异超过70个月。同样,NEIL2和TDG表达仅在某些亚型中与TMZ相关生存改变有关。
DNA修复基因内的功能性种系改变与TMZ敏感性相关,通过胶质瘤成人患者的总生存来衡量。这些变异应在前瞻性分析和功能研究中进行评估。